Integra LifeSciences Stock Forecast, Price & News

-0.99 (-1.43 %)
(As of 09/16/2021 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
Volume253,228 shs
Average Volume373,592 shs
Market Capitalization$5.78 billion
P/E Ratio28.33
Dividend YieldN/A
30 days | 90 days | 365 days | Advanced Chart
Receive IART News and Ratings via Email

Sign-up to receive the latest news and ratings for Integra LifeSciences and its competitors with MarketBeat's FREE daily newsletter.

Integra LifeSciences logo

About Integra LifeSciences

Integra LifeSciences Holdings Corp. engages in the manufacture and sale of medical instruments, devices, and equipment. It operates through the Codman Specialty Surgical, and Orthopedics and Tissue Technologies segments. The Codman Specialty Surgical segment refers to the company's neurosurgery business, which sells a full line of products for neurosurgery and neuro critical care such as tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and precision tools and instruments business, which sells instrument patterns and surgical and lighting products to hospitals, surgery centers, and dental, podiatry, and veterinary offices. The Orthopedics and Tissue Technologies segment includes offerings such as skin and wound repair, bone and joint fixation implants in the upper and lower extremities, bone grafts, and nerve and tendon repair. The company was founded by Richard E. Caruso in 1989 and is headquartered in Princeton, NJ.


See More Headlines

Industry, Sector and Symbol

Sales & Book Value





Social Links


Overall MarketRank

1.76 out of 5 stars

Medical Sector

810th out of 1,352 stocks

Surgical & Medical Instruments Industry

81st out of 123 stocks

Analyst Opinion: 1.1Community Rank: 4.1Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 1.9 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles

Integra LifeSciences (NASDAQ:IART) Frequently Asked Questions

Is Integra LifeSciences a buy right now?

8 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Integra LifeSciences in the last year. There are currently 1 sell rating, 4 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" Integra LifeSciences stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in IART, but not buy additional shares or sell existing shares.
View analyst ratings for Integra LifeSciences
or view top-rated stocks.

What stocks does MarketBeat like better than Integra LifeSciences?

Wall Street analysts have given Integra LifeSciences a "Hold" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Integra LifeSciences wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is Integra LifeSciences' next earnings date?

Integra LifeSciences is scheduled to release its next quarterly earnings announcement on Wednesday, October 27th 2021.
View our earnings forecast for Integra LifeSciences

How were Integra LifeSciences' earnings last quarter?

Integra LifeSciences Holdings Co. (NASDAQ:IART) posted its quarterly earnings results on Tuesday, July, 27th. The life sciences company reported $0.79 earnings per share (EPS) for the quarter, beating the Zacks' consensus estimate of $0.66 by $0.13. The life sciences company earned $389.99 million during the quarter, compared to analyst estimates of $376.11 million. Integra LifeSciences had a net margin of 13.62% and a trailing twelve-month return on equity of 17.64%.
View Integra LifeSciences' earnings history

How has Integra LifeSciences' stock been impacted by COVID-19?

Integra LifeSciences' stock was trading at $46.08 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, IART shares have increased by 48.2% and is now trading at $68.28.
View which stocks have been most impacted by COVID-19

When did Integra LifeSciences' stock split? How did Integra LifeSciences' stock split work?

Integra LifeSciences's stock split before market open on Tuesday, January 3rd 2017. The 2-1 split was announced on Thursday, December 22nd 2016. The newly minted shares were issued to shareholders after the market closes on Wednesday, December 21st 2016. An investor that had 100 shares of Integra LifeSciences stock prior to the split would have 200 shares after the split.

What guidance has Integra LifeSciences issued on next quarter's earnings?

Integra LifeSciences issued an update on its FY 2021 earnings guidance on Wednesday, August, 4th. The company provided earnings per share guidance of $2.980-$3.050 for the period, compared to the Thomson Reuters consensus EPS estimate of $2.920. The company issued revenue guidance of $1.54 billion-$1.55 billion, compared to the consensus revenue estimate of $1.53 billion.

What price target have analysts set for IART?

8 Wall Street analysts have issued 1 year target prices for Integra LifeSciences' stock. Their forecasts range from $50.00 to $88.00. On average, they expect Integra LifeSciences' share price to reach $72.89 in the next year. This suggests a possible upside of 6.7% from the stock's current price.
View analysts' price targets for Integra LifeSciences
or view top-rated stocks among Wall Street analysts.

Who are Integra LifeSciences' key executives?

Integra LifeSciences' management team includes the following people:
  • Peter J. Arduini, President, Chief Executive Officer & Director
  • Glenn G. Coleman, Chief Operating Officer & Executive Vice President (LinkedIn Profile)
  • Carrie Anderson, Chief Financial Officer, Treasurer & Executive VP
  • William Compton, Chief Information Officer & Senior Vice President
  • Kenneth E. Burhop, Chief Scientific Officer & Vice President

What is Peter J. Arduini's approval rating as Integra LifeSciences' CEO?

173 employees have rated Integra LifeSciences CEO Peter J. Arduini on Peter J. Arduini has an approval rating of 74% among Integra LifeSciences' employees.

Who are some of Integra LifeSciences' key competitors?

What other stocks do shareholders of Integra LifeSciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Integra LifeSciences investors own include The Boeing (BA), NVIDIA (NVDA), AbbVie (ABBV), Adobe (ADBE), Advanced Micro Devices (AMD), Gilead Sciences (GILD), Intel (INTC), Marvell Technology (MRVL), Alexion Pharmaceuticals (ALXN) and Abbott Laboratories (ABT).

What is Integra LifeSciences' stock symbol?

Integra LifeSciences trades on the NASDAQ under the ticker symbol "IART."

Who are Integra LifeSciences' major shareholders?

Integra LifeSciences' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Vanguard Group Inc. (7.86%), Champlain Investment Partners LLC (7.70%), Cooke & Bieler LP (3.25%), Clearbridge Investments LLC (3.02%), Macquarie Group Ltd. (1.66%) and Dimensional Fund Advisors LP (1.38%). Company insiders that own Integra LifeSciences stock include Eric Schwartz, Glenn Coleman, Jeffrey Mosebrook, Lisa Evoli, Peter J Arduini, Raymond G Murphy, Richard E Caruso, Stuart Essig and Tru St Partnership, LP.
View institutional ownership trends for Integra LifeSciences

Which institutional investors are selling Integra LifeSciences stock?

IART stock was sold by a variety of institutional investors in the last quarter, including Nuveen Asset Management LLC, AQR Capital Management LLC, Jennison Associates LLC, Parametric Portfolio Associates LLC, Atlanta Capital Management Co. L L C, Russell Investments Group Ltd., Champlain Investment Partners LLC, and Legal & General Group Plc. Company insiders that have sold Integra LifeSciences company stock in the last year include Eric Schwartz, Glenn Coleman, Jeffrey Mosebrook, Lisa Evoli, Raymond G Murphy, Stuart Essig, and Tru St Partnership, LP.
View insider buying and selling activity for Integra LifeSciences
or view top insider-selling stocks.

Which institutional investors are buying Integra LifeSciences stock?

IART stock was acquired by a variety of institutional investors in the last quarter, including Dimensional Fund Advisors LP, Macquarie Group Ltd., Goldman Sachs Group Inc., Bridgewater Associates LP, Edgestream Partners L.P., Renaissance Technologies LLC, Healthcare of Ontario Pension Plan Trust Fund, and Cooke & Bieler LP.
View insider buying and selling activity for Integra LifeSciences
or or view top insider-buying stocks.

How do I buy shares of Integra LifeSciences?

Shares of IART can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Integra LifeSciences' stock price today?

One share of IART stock can currently be purchased for approximately $68.28.

How much money does Integra LifeSciences make?

Integra LifeSciences has a market capitalization of $5.78 billion and generates $1.37 billion in revenue each year. The life sciences company earns $133.89 million in net income (profit) each year or $2.45 on an earnings per share basis.

How many employees does Integra LifeSciences have?

Integra LifeSciences employs 3,700 workers across the globe.

What is Integra LifeSciences' official website?

The official website for Integra LifeSciences is

Where are Integra LifeSciences' headquarters?

Integra LifeSciences is headquartered at 311 ENTERPRISE DRIVE, PLAINSBORO NJ, 08536.

How can I contact Integra LifeSciences?

Integra LifeSciences' mailing address is 311 ENTERPRISE DRIVE, PLAINSBORO NJ, 08536. The life sciences company can be reached via phone at (609) 275-0500 or via email at [email protected]

This page was last updated on 9/16/2021 by Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.